JAK选择性在炎症性肠病治疗中的临床意义
该综述批判性回顾了JAK抑制剂对JAK亚型差异选择性的临床前与临床数据,并总结正在研发的选择性JAK抑制剂在溃疡性结肠炎和克罗恩病中的潜在临床意义。托法替尼作为泛JAK抑制剂已获批用于中重度溃疡性结肠炎,但选择性抑制JAK亚型是否带来更优疗效或安全性仍有争议。
要点
- 托法替尼是泛JAK抑制剂,已获批用于中重度溃疡性结肠炎。
- 多种第二代亚型选择性JAK抑制剂正在研发中。
- 选择性抑制JAK亚型能否提高疗效或安全性仍存争议。
核心结论
- 选择性抑制JAK亚型是否与临床疗效提高和/或安全性改善相关仍存争议。
- 本综述旨在批判性回顾JAK抑制剂差异选择性的临床前与临床数据,并总结在研选择性JAK抑制剂对溃疡性结肠炎和克罗恩病的潜在临床意义。
研究设计与样本
- 综述类文章,检索范围原文未报告。
主要发现
- JAK为酪氨酸激酶,结合不同胞内细胞因子受体,导致信号转导及转录激活因子磷酸化,参与靶基因转录。
- 已描述四种JAK亚型:JAK1、JAK2、JAK3和TYK2。
- 口服JAK抑制剂作为协同抗细胞因子治疗在炎症性肠病中研发,对JAK亚型显示不同选择性。
- 托法替尼为泛JAK抑制剂,近期获批用于中重度溃疡性结肠炎治疗。
- 为改善该类药物的获益风险比,多种第二代亚型选择性JAK抑制剂正在研发中。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The two major forms of inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are chronic immune-mediated conditions characterised by an increased production of pro-inflammatory cytokines that act as critical drivers of intestinal inflammation. Anti-cytokine therapy has been shown to improve clinical outcomes in IBD. Janus kinases (JAKs) are tyrosine kinases that bind different intracellular cytokine receptors, leading to phosphorylation of signal transducer and activation of transcription molecules implicated on targeted gene transcription. Four isoforms of JAKs have been described: JAK1, JAK2, JAK3 and TYK2. Oral JAK inhibitors (JAKi) have been developed as synergic anti-cytokine therapy in IBD, showing different selectivity towards JAK isoforms. Tofacitinib, a pan-JAK inhibitor, has been recently approved for the treatment of moderate-to-severe UC. With the aim of improving the benefit: risk ratio of this drug class, several second-generation subtype-selective JAKi are under development. However, whether selective inhibition of JAK isoforms is associated with an increased clinical efficacy and/or a better safety profile remains debatable. The aim of this review is to critically review the preclinical and clinical data for the differential selectivity of JAK inhibitors and to summarise the potential clinical implications of the selective JAK inhibitors under development for UC and CD.
引用
- Danese S, Argollo M, Le Berre C, et al. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019. PMID: 31227590. doi:10.1136/gutjnl-2019-318448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。